Asahi Kasei buys German biotech Aicuris for USD 921M to expand infectious disease portfolio

GERMANY—Asahi Kasei has agreed to purchase all issued shares of Aicuris Anti-infective Cures, a German pharmaceutical company, for approximately €780 million (USD 920.7 million).

This strategic acquisition represents a decisive expansion of the Japanese conglomerate’s specialty pharmaceutical footprint, particularly in the treatment of severe infectious diseases affecting vulnerable patient populations.

Strengthening care for complex patients

The acquisition directly aligns with Asahi Kasei’s mission to develop a focused, sustainable specialty pharma platform serving immunocompromised and medically complex patients.

The company recognizes severe infectious diseases as strategically adjacent to its existing core businesses in transplantation through Veloxis and kidney disease management through Calliditas.

This connection holds particular significance, as infection-related complications pose substantial risks for patients requiring transplant care and nephrology treatment.

The Japanese pharmaceutical giant expects the transaction to conclude during the first quarter of fiscal 2026, subject to standard regulatory conditions.

While the company will record a positive impact on operating income starting in fiscal 2028, following standard amortization of goodwill and intangible assets, the long-term benefits position this deal as a foundational investment in future growth.

Expanding commercial reach

Asahi Kasei brings considerable competitive advantages to this acquisition through its established commercial infrastructure and advanced research capabilities.

The company intends to leverage its existing networks within transplant centers and nephrology providers to accelerate the commercialization of Aicuris’ drug candidates.

This integrated approach combines proven distribution channels with enhanced research and development resources, positioning new therapies for faster market entry.

A diversified drug portfolio

Aicuris contributes three distinct pharmaceutical compounds to Asahi Kasei’s growing portfolio.

Prevymis (letermovir) already generates substantial royalty revenue, providing immediate financial contribution.

Pritelivir represents a near-term catalyst, with regulatory approval expected during fiscal year 2026.

AIC468 offers longer-term growth potential, collectively creating a multi-tiered strategy that delivers both near-term revenue stability and future commercial opportunities.

Part of a broader strategic vision

Ken Shinomiya, head of Asahi Kasei’s healthcare sector, described the acquisition as strengthening the company’s position across interconnected therapeutic areas, including autoimmune diseases, transplantation, kidney disease, and severe infectious diseases.

The company executed this transaction with strategic discipline and agility to advance long-term growth objectives within its “Trailblaze Together” management initiative.

This acquisition reinforces Asahi Kasei’s commitment to high-growth opportunities within specialty pharmaceuticals.

The company previously demonstrated this strategic focus in May 2024 through a public cash offer to acquire Swedish drugmaker Calliditas for Skr11.16 billion (USD 1.04 billion), confirming a sustained investment trajectory in specialized therapeutic areas.